Cookies on this site

A new study led by the Fairfax Group at the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

Doctor checking a mole on a patient's back.

Cytomegalovirus (CMV) is a common virus that, while typically asymptomatic, is carried for life by around 50–60% of UK adults*. In healthy individuals, CMV is kept in a dormant state by the immune system; however, this process profoundly reshapes how the immune system operates. The study - published in Nature Medicine - explored how CMV affected the immune responses of 341 melanoma patients receiving immunotherapy, a form of cancer treatment that helps harness the immune system to recognise and fight cancer.

Melanoma is a cancer of the skin that can be difficult to cure if not caught early. Immunotherapies have improved the survival rates of melanoma, but not all patients benefit, and some go on to develop resistance. Occasionally, patients develop side-effects from immunotherapy (especially those receiving combination treatments), which can be life-changing and, in some cases, fatal.

This research, which is the first of its kind, suggests that CMV infection may improve treatment outcomes in melanoma patients receiving less intensive immunotherapy, while also markedly reducing the frequency of severe side-effects. The researchers also found that CMV infection potentially delays melanoma from developing and spreading, indicating that the immune response to CMV might also impact cancer development.

Senior author, Professor Ben Fairfax said:

Current immunotherapies for cancer can cause serious side-effects in some patients, which may occasionally lead to lifelong complications. Prior CMV infection in a patient could help determine, on a patient-by-patient basis, whether immunotherapies are likely to be effective or cause side-effects, serving as a key factor in deciding which treatments to give.

Our work also has potentially fundamental implications for our understanding of skin cancer development, because it shows that factors which influence the immune system independently of cancer can have unanticipated effects on melanoma development.

Read the full story on Oxford Cancer's website.

Read the journal article here: https://doi.org/10.1038/s41591-025-03647-1

Recent stories

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Expanding OxCITE: New funding to accelerate immunotherapy research

New funding from Cancer Research Horizons will help researchers to better understand why some patients respond well to immunotherapy while others do not.

A summer of science and engagement

This summer, researchers at the MRC WIMM have taken part in a variety of public engagement activities, leading a stand at Cheltenham Science Festival and welcoming students for the Institute's summer work experience programme.

WIMM Day 2026: connecting people, ideas and scientific discovery

On Tuesday 23rd June, the MRC WIMM community came together at Saïd Business School for the Institute's annual away day, sharing research, professional achievements and much more.

Professor Adam Mead joins Oxford Cancer leadership team

Congratulations to Adam Mead, who has been appointed Director of Oxford Cancer. Professor Mead joins Professors Mark Middleton and Tim Elliott in leading Oxford’s interdisciplinary cancer research community.

Paresh Vyas receives CRUK Discovery Programme Award

Congratulations to Professor Paresh Vyas, who has been awarded a Discovery Research grant from Cancer Research UK to investigate cancer immunotherapies.